Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia

Bowen, A; Zomas, Athanasios; Emmett, E.; Matutes, Estella; Dyer, Martin J. S.; Catovsky, Daniel

doi:10.1046/j.1365-2141.1997.d01-2061.x

Cited by 122 publications

(63 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22][23][24][25] Among them, humanized and chimeric monoclonal antibodies [26][27][28][29][30][31] and particularly the anti-CD20 antibody rituximab [32][33][34][35][36][37][38][39][40] have received special attention. This is due to several attractive properties of monoclonal antibodies such as:…”

Section: Introductionmentioning

confidence: 99%

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

et al. 2001

View full text Add to dashboard Cite

The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pretreated patients this treatment also showed promising results, although the risk of severe infections needs to be considered. Leukemia (2001Leukemia ( ) 15, 1941Leukemia ( -1949

show abstract

Section: Introductionmentioning

confidence: 99%

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

et al. 2001

View full text Add to dashboard Cite

show abstract

“…This antibody is being developed for the treatment of CLL. 13,14 CAMPATH-1H is a human IgG1, chosen for its optimal effector function and in principle it should be equally as effective as CAMPATH-1G for elimination of T cells in vivo. There is already a lot of data to support this concept from clinical trials with CAMPATH-1H in CLL, rheumatoid arthritis, multiple sclerosis and organ transplantation.…”

mentioning

confidence: 99%

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

Hale

Jacobs²,

Wood³

et al. 2000

Bone Marrow Transplant

154

View full text Add to dashboard Cite

Summary:Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T cell depletion increases the risk of graft rejection. In this study, two strategies are used to overcome rejection: (1) use of high doses of stem cells obtained from peripheral blood (PBSC), (2) admixture with a CD52 monoclonal antibody in order to deplete both donor and residual recipient lymphocytes. Two antibodies are compared: CAMPATH-1G (rat IgG2b) and its humanized equivalent CAMPATH-1H (human IgG1). A total of 187 consecutive patients at six centers received PBSC transplants from HLA-matched siblings between 1997 and 1999. A wide spectrum of diseases, both malignant and non-malignant, was included. The recovery of CD34 + cells after antibody treatment was close to 100%. The risk of acute GVHD (grade 2 to 4) was 11% in the CAMPATH-1G group and 4% in the CAMPATH-1H group (P = NS). The risk of chronic GVHD (any grade) was 11% in the CAMPATH-1G group and 24% in the CAMPATH-1H group (P = 0.03) but the risk of extensive chronic GVHD was only 2%. The overall risk of graft failure/rejection was 2%, not significantly different between the two antibodies. Antibody treatment was equally effective at concentrations between 10 g/ml and 120 g/ml and it made no significant difference to the outcome whether the patients received post-transplant immunosuppression or not (87% did not). Transplant-related mortality in this heterogenous group of patients (including high-risk and advanced disease) was 22% at 12 months. It is proposed that treatment of peripheral blood stem cells with CAMPATH-1H is a simple and effective method for depleting T cells which may be applicable to both autologous and allogeneic

show abstract

“…[112][113][114][115][116][117][118] CAMPATH-1H is especially active in the treatment of T cell prolymphocytic leukemia (T-PLL). 119 A response rate of 73% (11 of 15 patients) with nine (60%) entering complete response was observed in chemotherapy-resistant T-PLL patients following treatment with this antibody.…”

Section: Leukemiamentioning

confidence: 99%

“…Studies of CAMPATH-1H in CLL have been conducted in previously untreated patients and in patients pretreated with FAMP or alkylating agents. [116][117][118] In the vast majority of CLL patients CAMPATH-1H causes constant reduction of abnormal blood lymphocytosis, usually in less than 4 weeks, and disappearance of CD5/CD19 co-expression cells from blood. The regression of lymphoid infiltration from other sites, especially from lymph nodes, is less clear.…”

Section: Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

Robak

Kasznicki

2002

Leukemia

View full text Add to dashboard Cite

Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia

Cited by 122 publications

References 8 publications

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

Contact Info

Product

Resources

About